MRSN (Mersana Therapeutics) Buyback Yield % : -13.07 (As of Apr. 22, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Mersana Therapeutics's current buyback yield was -13.07%.

Mersana Therapeutics Buyback Yield % Historical Data

The historical data trend for Mersana Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Buyback Yield % Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-12.39

-9.40

-24.49

-33.40

-3.49

Mersana Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-33.40	-14.17	-2.31	-2.49	-3.49

Competitive Comparison of Mersana Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Mersana Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Mersana Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Mersana Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	5.78)	/	165.3795
	=	-3.49%

Mersana Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	5.78)		/	165.3795
	=	-3.49%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Mersana Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (NAS:MRSN) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

0M4:Germany

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Executives

Anna Protopapas	director, officer: President and CEO	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Mohan Bala	officer: SVP, Chief Development Officer	C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Deschuytner	officer: Sr. VP, Finance & Product stgy	840 MEMORIAL DRIVE, CAMBRIDGE MA 01776
Huber Martin H. Jr.	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Ashish Mandelia	officer: VP, Controller	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Timothy B Lowinger	officer: Chief Scientific Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alejandra Carvajal	officer: Chief Legal Officer	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Tushar Misra	officer: Chief Manufacturing Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Arvin Yang	officer: Chief Medical Officer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Michael J. Kaufman	officer: Sr VP Chmistry, Man & Control	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Eva M. Jack	officer: CBO, Treasurer & Secretary	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451